This phase II trial is evaluating the effectiveness of a targeted therapy (trametinib) in children, teenagers and young adults with neurofibromatosis type 1 (NF1) associated Plexiform Neurofibromas and Optic Pathway Gliomas.
This trial is treating patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)
This trial has two cohorts. Cohort 1 will consist of people with Neurofibromatosis Type 1 associated Plexiform Neurofibroma (NF1-PN). Cohort 2 will consist of people with Neurofibromatosis Type 1 associated Optic Pathway Glioma (NF1-OPG). To be eligible, participants must be aged between 3 months and 25 years. All participants will receive trametinib either as an oral tablet or an oral solution. Trametinib will be administered at a dose of 0.025mg/kg once daily for children 6 years and over, and at a dose of 0.032mg/kg once daily for children under 6 years.
Recruiting Hospitals Read More